In Vivo Imaging and Selective Drug Delivery Using Molecular Signature-Targeted Peptide Probes
Professor of Biochemistry and Cell Biology
Kyungpook National University
January 12, 2017
12:30 p.m. - 1:20 p.m.
Foege N130A, Wallace H. Coulter Seminar Room
A growing body of evidence shows that pathological lesions put novel molecular signatures on their tissues and vasculatures. We have identified peptide probes that recognize and target such molecular signatures by screening phage displayed-peptide library. In this talk, I will introduce these molecular signature-targeted (MOST) peptide probes and their application to imaging and drug delivery. For example, IL4RPep-1 (IL-4 receptor-binding peptide-1), with the sequence of CRKRLDRNC homologous with IL-4, bound to H226 lung tumor cells that over-express IL-4 receptor. When injected intravenously into nude mice bearing a subcutaneous tumor, near-infrared fluorescence (NIRF) dye and IL4RPep-1-labeled liposomes selectively homed to H226 tumor and more efficiently inhibited tumor growth than untargeted liposomes. As another example, ApoPep-1 (apoptosis-targeting peptide-1), with the sequence of CQRPPR that binds to histone H1 exposed on the surface of apoptotic cells, homed to apoptotic areas at tumor tissue. ApoPep-1 bound to apoptotic tumor cells on culture at higher levels than that to healthy cells. In vivo imaging of apoptosis using NIRF-labeled ApoPep-1 could enable early monitoring of tumor response to chemotherapy. Taken together, MOST peptide probes will be a useful tool for imaging and diagnosis of pathologic lesions and selective drug delivery.
Byungheon Lee is currently a Professor in Department of Biochemistry and Cell Biology at Kyungpook National University (KNU) and Director of Tumor Heterogeneity and Network (THEN) Research Center at KNU. He received his B.S. from School of Medicine, KNU in 1989 and his M.S. and Ph.D. in Biochemistry from KNU in 1991 and 1995, respectively. He received his M.D. from Korean Medical Association in 1989. He was a visiting investigator in Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA in 2001-2003. He joined KNU in 2003. He is currently a member of Korean Society for Biochemistry and Molecular Biology, American Association for Cancer Research, American Society of Molecular Imaging, and American Society for Controlled Release. He has published over 70 peer-reviewed papers, 3 book chapters, and 1 review article. He also filed 50 domestic and international patents. His main research interest is the discovery of tissue-specific homing peptides using phage display and their applications to molecular imaging and targeted drug delivery. He is currently carrying out projects for interleukin-4 receptor-targeted imaging and therapy of cancer, in vivo molecular imaging of apoptosis using peptide probes, and development of sensing peptides for disease biomarkers.